Macrovascular complications are responsible for the high morbidity and mortality in patients with diabetes. Peroxisome proliferatoractivated receptor c (PPARc) plays a central role in the process of adipocyte differentiation and insulin sensitization, and also possesses anti-atherogenic effects. Recently, some statins, angiotensin II type 1 receptor blockers and calcium channel blockers have been reported to activate PPARc. However, the impact of PPARc activation on diabetic macrovascular complications is not fully understood. It has been reported that the activation of PPARc by thiazolidinediones induces anti-atherogenic effects in vascular cells, including monocytes/macrophages, endothelial cells and smooth muscle cells, in atherosclerotic animal models and in clinical studies. We have reported that hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), which are used for treatment of hypercholesterolemia, activate PPARc and mediate anti-atherogenic effects through PPARc activation in macrophages. Also, telmisartan, an angiotensin type I receptor blocker, has been reported to have anti-atherogenic effects through PPARc activation. Furthermore, we have reported that nifedipine, a dihydropyridine calcium channel blocker, can activate PPARc, thereby mediating anti-atherogenic effects in macrophages. Therefore, statin therapy and part of anti-hypertensive therapy might produce beneficial effects through PPARc activation in hypercholesterolemic and/or hypertensive patients with diabetes, and PPARc might be a therapeutic target for diabetic macrovascular complications. In the present review, we focus on the anti-atherogenic effects of PPARc and suggest potential therapeutic approaches to prevent diabetic macrovascular complications. (J Diabetes Invest,
INTRODUCTION
Diabetic macrovascular complications, including cardiovascular disease (CVD), stroke and peripheral vascular disease, are mainly responsible for the high morbidity and mortality of diabetes patients [1] [2] [3] . Several longitudinal epidemiological studies have shown that the risk of mortality from CVD in diabetic subjects is more than double compared with age-matched healthy subjects 4, 5 , suggesting that some features of diabetes, such as hyperglycemia, must promote an excessive tendency toward CVD.
Hyperglycemia is a diagnostic feature of diabetes, a target for antidiabetic therapy and a marker of glycemic control together with HbA 1c . Conserving good glycemic control has been associated with a notable reduction in the risk of developing retinopathy, nephropathy and neuropathy in both type 1 6 and type 2 7, 8 diabetic patients. Furthermore, when the therapy is started in the early stages of diabetes, intensive diabetes therapy has longterm beneficial effects on the risk of CVD in both type 1and type 2 diabetes 9 . There are several lines of evidence showing that the risk of cardiovascular mortality increases with the elevation in plasma glucose concentrations and HbA 1c levels 10, 11 . However, although the effect of plasma glucose levels appears to be preponderant in determining the microvascular risk, this does not seem to be the case for macrovascular complications.
The UK Prospective Diabetes Study (UKPDS) clearly shows that for the same degree of HbA 1c , particularly in its low range, the incidence of myocardial infarction is much greater than that of retinopathy 12 . This apparent paradox can only be resolved by acknowledging the multifactorial nature of the cardiovascular risk in type 2 diabetic subjects. The UKPDS identified several potentially modifiable risk factors, including hypercholesterolemia and hypertension, as well as hyperglycemia, for CVD in type 2 diabetes 13 . Furthermore, HbA 1c was found to be the third most important factor in determining the cardiovascular risk 7 . Indeed, several intervention studies have reported that lipid lowering with hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) reduces the incidence of cardiovascular events in patients with diabetes [14] [15] [16] [17] [18] [19] [20] . In addition, the HOT study 21 and UKPDS 39 22 showed that lowering blood pressure decreased the risk of CVD in hypertensive patients with diabetes. Indeed, several studies have reported that treatment with angiotensin II converting enzyme inhibitor (ACEI) 23 , angiotensin II type 1 receptor (AT1R) blocker (ARB) 24 or calcium channel blockers (CCB) 21, 25 reduced the incidence of cardiovascular events in hypertensive patients with diabetes. Therefore, it is very important for the prevention of diabetic macroangiopathy to enforce antihypercholesterolemic and antihypertensive therapy in diabetic patients.
Recently, it has been reported that some statins, ARB and CCB activate peroxisome proliferator-activated receptor c (PPARc), which plays a central role in the process of adipocyte differentiation, peripheral glucose utilization and insulin sensitization, and has anti-atherogenic effects. In the present review, we examine the possibility of therapeutic approaches for the prevention of diabetic macrovascular complications through PPARc activation.
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR c
Peroxisome proliferator-activated receptor c, a member of the nuclear hormone receptor family of ligand-dependent transcription factors 26 , has been well characterized as a regulator of adipogenesis and is abundant in fat cells 27 . Two major splice isoforms of PPARc, PPARc1 and PPARc2, have been identified in mice, whereas in humans and other species at least two other isoforms, PPARc3 and PPARc4, have been detected 28 . Several endogenous ligands for PPARc, including polyunsaturated fatty acids such as linoleic acid, arachidonic acid and eicosapentaenoic acids, have been identified. Prostaglandin-related compounds, such as 15 deoxy-D 12, 14 -prostaglandin J 2 (15d-PGJ 2 ), 9-and 13-hydroxyoctadecadienoic acid, 12-and 15-hydroxyeicosatetaenoic acid and nitro lipids, have also been identified as beneficial PPARc agonists [29] [30] [31] [32] . Thiazolidinediones (TZD), including pioglitazone and rosiglitazone, which are currently on the market, are the most notable synthetic compounds with PPARc activation properties that improve insulin resistance and lower blood glucose levels in type 2 diabetes.
Peroxisome proliferator-activated receptor c forms a heterodimer with another nuclear receptor, retinoid X receptor a (RXRa), and binds to a specific DNA sequence, termed PPAR response element 5¢-AAGGTCAnAAGGTCA-3¢ (PPRE), in the regulatory regions of target genes 33 . In addition, PPARc can regulate gene expression independently of PPRE, either by suppressing growth hormone protein-1, a transcription factor involved in pituitary-specific gene expression, or by interfering with the function of activator protein (AP)-1, signal transducer and activator of transcription (STAT)-1 and nuclear factor jB (NF-jB) [34] [35] [36] [37] . Coactivators, including steroid receptor coactivator-1, p300/ cAMP response element binding protein (CBP), general control non-repressed/p300/CBP-associated factor and PPARc coactivator, can bind PPARc/RXRa complexes in a ligand-dependent manner 38 . In contrast, mitotic, stress and inflammatory signals cause PPARc degradation through phosphorylation on Ser84 of the mouse PPARc (Ser112 of the human molecule), which is in a consensus mitogen-activated protein kinase (MAPK) target motif PXSPP 39 , by extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinases and p38 MAPK, which leads to ubiquitination and proteasomal degradation 40 . A Ser84 to Ala84 PPARc mutant shows increased transcriptional activity, and a similar effect is caused by coexpression with the dual-specificity (Thr/Tyr) MAPK phosphatase, CL100 39 . Peroxisome proliferator-activated receptor c plays a central role in the process of adipocyte differentiation, peripheral glucose utilization and insulin sensitization in adipocytes [41] [42] [43] [44] . In addition, PPARc is expressed in macrophages 36 , endothelial cells (EC) 45 , vascular smooth muscle cells (VSMC) 46 and in atherosclerotic lesions 47, 48 . PPARc agonists suppressed the progression of atherosclerosis in low-density lipoprotein (LDL)-receptordeficient 49, 50 or apolipoprotein E-deficient (ApoE
) mice [51] [52] [53] ( Table 1) . In clinical studies, the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) study suggested that pioglitazone might decrease the occurrence of all-cause mortality, non-fatal myocardial infarction (MI) and non-fatal stroke in patients with type 2 diabetes mellitus and macrovascular diseases 54 . Mazzone et al. 55 showed that pioglitazone slowed the progression of carotid intima-media thickness compared with glimepiride in patients with type 2 diabetes. The Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation (PERISCOPE) study showed that treatment with pioglitazone resulted in a significantly lower progression rate of coronary atherosclerosis compared with glimepiride 56 . Ogasawara et al. 57 reported that pioglitazone might stabilize coronary plaque by reducing the necrotic-core component in Japanese patients with type 2 diabetes. These findings show the usefulness of PPARc activator in the treatment of diabetic macroangiopathy. In contrast, meta-analysis reported that treatment with rosiglitazone, but not with pioglitazone, was associated with increased incidence of MI 58, 59 . Because meta-analysis has many limitations and the increased risk of MI is still controversial, these reports should be carefully considered. However, several differences between the effects of pioglitazone and rosiglitazone do exist. For example, pioglitazone has more beneficial effects on the lipid profile than rosiglitazone 60 . Furthermore, rosiglitazone, but not pioglitazone, induced cardiac hypertrophy through a PPARc-independent pathway 61 . To clarify the mechanism(s) of the differences between the effects of pioglitazone and rosiglitazone, further studies are required.
THIAZOLIDINEDIONES
Thiazolidinediones, which are pharmacological ligands of PPARc, are used to treat patients with type c 2 diabetes. Several anti-atherosclerotic effects of TZD have been reported in various cell types existing in atherosclerotic lesions ( Figure 1 ). In EC, TZD inhibited the expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 62, 63 , decreased production of chemokines, such as interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) 64 , decreased endothelin-1, which is involved in the regulation of vascular tone and smooth muscle cell proliferation 45 , and increased nitric oxide (NO) release 65 . In addition, a recent report showed that adipose tissue-derived adiponectin plays an obligatory role in TZD-induced improvement of endothelial function in diabetic obese mice 66 . Vascular smooth muscle cells have pivotal roles in the progression of atherosclerosis, and recent studies have shown that they are key targets of TZD. In particular, proliferation of VSMC is one of the critical events in atherosclerosis and vascular intervention-induced restenosis. TZD inhibit these changes in VSMC and neointimal thickening after vascular injury 67 . TZD inhibited VSMC proliferation 67, 68 by decreasing phosphorylation of retinoblastoma protein and increasing levels of cyclin-dependent inhibitor p27 67 , and thus suppressed neointima thickening after vascular injury 69 . Furthermore, TZD induced apoptosis of VSMC through p53 and Gadd45 70, 71 . In addition, TZD inhibited the expression of matrix metalloproteinase-9 (MMP-9) 71 and VSMC migration 46, 68 , resulting in plaque stabilization. TZD also inhibited IL-1b-induced inducible NO synthase (iNOS) expression and NO production in VSMC 72 . Interestingly, TZD inhibited AT1R in VSMC [73] [74] [75] , suggesting that this downregulation would be beneficial for diabetic patients with hypertension.
The involvement of PPARc in regulating lipid metabolism in macrophages was initially suggested by the discovery of the class B scavenger receptor CD36 as a PPARc target gene in macrophages 76 . CD36, which is involved in the uptake of oxidized LDL (Ox-LDL), is thought to be a critical molecule in macrophage-derived foam cell formation 77 . In addition, CD36 is highly expressed in lipid-laden macrophages in human atherosclerotic plaques 78 , and 9-hydroxyoctadecadienoic acid and 13-hydroxyoctadecadienoic acid, which are components of the Ox-LDL particle, can activate PPARc, suggesting that the activation of PPARc is involved in the formation of foam cells and the progression of atherosclerosis 31 . However, treatment with TZD has been found to increase the apolipoprotein-AI-dependent efflux of cholesterol from both mouse and human macrophages 79, 80 . Strikingly, the ability of TZD to promote cholesterol efflux is completely dependent on the expression of adenosine triphosphate-binding cassette transporter A1 (ABCA1), which is characterized as a vital molecule in the control of high-density lipoprotein and apolipoprotein A1-mediated cholesterol efflux from macrophages 81, 82 through PPARc activation 80 . Thus, although TZD induce the expression of CD36 in macrophages, they simultaneously induce the expression of ABCA1 in these cells, thereby enhancing the removal of cholesterol from the vessel wall through PPARc activation.
Classically activated macrophages, known as M1 macrophages, express pro-inflammatory cytokines, whereas alternatively activated macrophages, known as M2 macrophages, express anti-inflammatory cytokines and play a protective role in the progression of atherosclerosis. Recent studies showed that PPARc is one of the key regulators of M1/M2 macrophage polarization 82 , and that TZD prime monocytes into M2 macrophages and PPARc expression is enhanced during differentiation of M2 macrophages 83, 84 . TZD suppress the expression of M1 macrophage-associated pro-inflammatory cytokines in monocytes, including tumor necrosis factor-a (TNF-a), IL-1b and IL-6 85 , and inhibit macrophage activation in vitro
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. Meanwhile, Marx et al. 47 reported that TZD inhibited MMP-9 gelatinolytic activity, an enzyme responsible for plaque rupture. A similar phenomenon was also observed in monocytes 86 . In association with these findings, TZD inhibited MCP-1-directed monocyte migration, which was mediated through a decrease in MMP-9 expression and/or increase in a tissue inhibitor of metalloproteinase-1 expression 87 .
One of the characteristic events in atherosclerotic lesions is cell proliferation in arterial walls, including VSMC and macrophages. Indeed, previous in vivo studies have reported that macrophages and macrophage-derived foam cells proliferated in atherosclerotic lesions [88] [89] [90] . We 91, 92 and other groups 93, 94 have shown that Ox-LDL enhanced macrophage proliferation and survival in vitro. Therefore, it is possible that macrophage proliferation promotes the progression of atherosclerosis. In relation to these findings, we have reported that TZD suppress Ox-LDL-induced macrophage proliferation 95 . Thus, the suppression of macrophage proliferation might be one of the anti-atherogenic effects of TZD.
Peroxisome proliferator-activated receptor c is thought to alter macrophage function at the molecular level through various mechanisms 38 . PPARc induces a ligand and a sumoylation-dependent conformational shift that allows direct binding to NF-jB and recruitment of the co-repressor complex, nuclear receptor corepressor, thereby suppressing transcription of NF-jB target genes, such as iNOS 96, 97 . TZD also inhibit the activity of other transcription factors, such as AP-1 and STAT-1, both of which are involved in the induction of pro-inflammatory cytokines during differentiation of M1 macrophages 36, 85 . As aforementioned, TZD might many antiatherogenic effects in vascular cells, and might be beneficial for diabetic macroangiopathy beyond the improvement of insulin sensitivity.
CHOLESTEROL-LOWERING THERAPY IN PATIENTS WITH DIABETES
Dyslipidemia, an established risk factor for CVD, is strikingly common in patients with type 2 diabetes, affecting almost 50% of this population 98 . In addition to hyperglycemia and hypertension, dyslipidemia is a modifiable CVD risk factor that remains largely uncontrolled in patients with diabetes 92 . HMG-CoA reductase inhibitors (statins) are known to reduce the incidence of cardiovascular events and death by functional changes of atherosclerotic lesions [99] [100] [101] [102] . Furthermore, because of these benefits, which were shown by many clinical studies, statin therapy is recommended as the initial pharmacological treatment for lowering LDL-cholesterol levels in patients with type 2 diabetes 103, 104 . These statin benefits are mainly achieved by its strong lipid-lowering effect. However, recent data suggest that many of the beneficial effects exerted by statins on vascular cells are independent of the cholesterol-lowering effect [105] [106] [107] [108] [109] . Cholesterol is synthesized through the isoprenoid biosynthetic pathway 110 . In this pathway, isopentenyl-PP is the basic isoprene unit used for synthesis of all subsequent isoprenoids 110 . Among the isoprenoids, farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) serve as important lipid attachments for several proteins, including the small GTP-binding protein Ras and Ras-like proteins, such as Rho, Rac and Cdc42, whose proper membrane localization and function are dependent on isoprenylation 110 . The pleiotropic effects of statins, which include improving the function of EC, VSMC and macrophages 110, 111 , are thought to be mediated by blocking the synthesis of FPP and GGPP, resulting in the inhibition of small GTP-binding proteins 110 . Several studies reported that atorvastatin and pravastatin increased PPARc activity in monocytes 112, 113 . We also showed that five lipophilic statins (simvastatin, cerivastatin, fluvastatin, atorvastatin and pitavastatin) can activate PPARc in macrophages 114 . We have shown that statins have a unique mechanism for PPARc activation (Figure 2 ). Statin-induced PPARc activation was suppressed by the addition of mevalonate, FPP or GGPP 114 . Moreover, farnesyl transferase inhibitor and geranylgeranyl transferase inhibitor mimicked the effects of statins. Furthermore, statins inhibited the membrane translocation of Ras, RhoA, Rac and Cdc42, and overexpression of dominantnegative mutants of RhoA and Cdc42, but not of Ras or Rac, increased PPARc activity 114 . Therefore, suppression of the mevalonate pathway and inactivation of RhoA and Cdc42 are involved in statin-mediated PPARc activation. In contrast, statins induced ERK1/2 and p38 MAPK activation, and ERK1/2-and p38 MAPK-specific inhibitors abrogated statin-induced PPARc activation, suggesting that statin-mediated PPARc activation was caused by the activation of ERK1/2 and p38 MAPK 114 . However, inhibition of RhoA and Cdc42 activated p38 MAPK, but not ERK1/2 114 . Therefore, statin-induced PPARc activation might be mediated by a RhoA-and Cdc42-dependent p38 MAPK pathway and by a RhoA-and Cdc42-independent ERK1/2 pathway 114 . A subsequent mechanism of PPARc activation by statins is a cyclooxygenase-2 (COX-2)-dependent increase in 15d-PGJ 2 , which is a natural ligand of PPARc 114 . Indeed, we showed that statins increased COX-2 expression and intracellular 15d-PGJ 2 levels, and statin-mediated PPARc activation was suppressed by selective COX-2 inhibitors or by downregulation of COX-2 using siRNA 114 . In relation to these findings, it has been reported that statins can induce COX-2 expression in VSMC 115 and macrophages 116 . Several studies have shown that statins suppressed the expression of TNF-a 117 and MCP-1 118 in macrophages. We showed that lipopolysaccharide (LPS)-induced expression of TNF-a and MCP-1 was suppressed by pitavastatin in macrophages, and these effects were abrogated by PPARc siRNA 114 . Furthermore, pitavastatin induced ABCA1 expression, and this effect was also abrogated by PPARc siRNA 114 . Argmann et al. 119 also reported that statins induced ABCA1 expression in macrophages, and this effect was suppressed by the PPARc antagonist, GW9662. These results suggest that PPARc activation is one of the key mechanisms in the pleiotropic effects of statins on atherosclerosis, and statin therapy might improve the atherogenic profile by dual effects, such as improving hypercholesterolemia and activating PPARc, in patients with diabetes.
ANTI-HYPERTENSIVE THERAPY IN PATIENTS WITH DIABETES
Several large randomized trials have reported that ACEI 23 , ARB 24 and dihydropyridine CCBs 21,25 prevented cardiovascular events in hypertensive patients with type 2 diabetes. Inhibition of RAS by either ACEI or ARB reduced atherosclerotic lesion formation in experimental studies using various models of atherosclerosis [120] [121] [122] [123] . Among the ARB, telmisartan has been identified as a ligand for PPARc 124, 125 . Indeed, we 126 and other groups [127] [128] [129] [130] reported that telmisartan suppressed the progression of atherosclerosis in apoE )/) mice (Table 2) . Similar results were shown in Watanabe heritable hyperlipidemic rabbits 131 ( Table 2) . Furthermore, it has been reported that telmisartan prevented ischemic brain damage through PPARc activation in normal 132 and diabetic mice 133 . Several studies elucidated that telmisartan has direct anti-atherogenic effects on vascular cells (Figure 3 ). In EC, telmisartan suppresses VCAM-1 expression and reactive oxygen species generation 134 , prevents methylglyoxal-mediated cell death 135 , increases the permeability of EC 136 and induces proliferation of endothelial progenitor cells 137 . In VSMC, telmisartan suppresses cell proliferation 138 and AT1R expression 139 . We showed that in macrophages, telmisartan inhibits TNF-a and MCP-1 expression through inactivation of NF-jB, induces ABCA1/ABCG1 expression through activation of liver X receptor and inhibits Ox-LDL-induced cell -prostaglandin J 2 ; MCP-1, monocyte chemoattractant protein-1; NF-jB, nuclear factor-jB; TNF-a, tumor necrosis factor-a. . Nakaya et al.
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also reported that telmisartan induced ABCA1/ABCG1 expression through PPARc in THP-1 macrophages. These reports suggest that telmisartan has the capacity to prevent atherosclerosis by not only lowering blood pressure, but also activating PPARc. Dihydropyridine CCB are relevant treatments for patients with hypertension. Beyond causing vasodilatation by inhibiting calcium cannels, dihydropyridine CCB provide clinical benefits in patients with coronary artery disease that might be independent of blood pressure reductions 141, 142 . Nifedipine, one of the dihydropyridine CCB, reduced the atherosclerotic plaque area in cholesterol-fed rabbits [143] [144] [145] (Table 3) , and suppressed the progression of atherosclerosis in hypertensive patients [146] [147] [148] [149] [150] . Recently, we showed that nifedipine could activate PPARc in macrophages, which was not observed by amlodipine or Ca 2+ chelator, suggesting that this effect was not caused by blocking calcium influx 151 . Unlike telmisartan, nifedipine does not act as a direct PPARc ligand, but suppresses PPARc phosphorylation by inhibiting ERK1/2 activity, thereby activating PPARc (Figure 4) 
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. The exact mechanism of nifedipine-mediated inactivation of ERK1/2 is still unknown. However, Mulvaney et al. 152 reported that nifedipine suppressed buserelin (a gonadotropin-releasing hormone agonist)-induced ERK1/2 activation through inactivation of Raf in aT3-1 cells, an immortalized mouse pituitary cell line. In this report, the authors speculated that the inactivation of Raf was caused by blocking L-type calcium channels and, subsequently, inhibiting calcium influx. However, we found that amlodipine did not activate PPARc 152 . Thus, there might be mechanism(s) other than calcium influx inhibition for nifedipine-mediated inactivation of the Raf/ERK pathway. Hirata et al. 153 reported that nifedipine suppressed ERK1/2 activation by inhibiting proline-rich tyrosine kinase-2 (Pyk2) in VSMC. Therefore, inactivation of Pyk2 might also be involved in nifedipine-mediated inactivation of ERK1/2 in macrophages. Further studies are required to clarify the exact mechanism(s) of the nifedipine-mediated inactivation of ERK1/2.
Several studies reported multiple anti-atherogenic effects of nifedipine in vascular cells. Especially in macrophages and human peripheral blood mononuclear cells, nifedipine suppressed the LPS-induced increase of iNOS 154 and inflammatory cytokines, such as TNF-a, IL-1b and interferon-c 155 . Furthermore, nifedipine inhibited the LPS-induced NF-jB activation 156 . In addition to these previous reports, we recently showed that nifedipine suppressed the LPS-induced MCP-1 expression and NF-jB activation through PPARc activation in macrophages 151 . These findings are supported by a previous report showing that nifedipine suppressed angiotensin II-induced MCP-1 expression through NF-jB inhibition in rat VSMC 157 . In contrast, Suzuki et al. 158 reported that nifedipine induced ABCA1 expression and apolipoprotein-mediated release of cellular cholesterol in macrophages. We also showed that nifedipine induced ABCA1 expression through PPARc activation 151 . Furthermore, our in vivo study showed that nifedipine suppressed the acceleration of atherosclerosis (Table 3) , decreased MCP-1 expression, and increased ABCA1 expression and PPARc activation in apoE )/) mice 151 . Our recently proposed novel mechanism of nifedipinemediated PPARc activation is supported by other reports using the PPARc antagonist, GW9662 [159] [160] [161] . Taking these findings into consideration, nifedipine, as well as telmisartan, might have anti-atherogenic effects through PPARc activation beyond the lowering of blood pressure, and treatment with such anti-hypertensive drugs might be beneficial for the prevention of atherosclerosis in hypertensive patients with diabetes.
CONCLUSIONS
The progression of diabetic macrovascular complications is caused by endothelial injury, activation of macrophages and abnormality of VSMC function. The mechanisms of anti-atherogenic effects by PPARc are mainly dependent on the improvement of endothelial biology, and inactivation of macrophages and VSMC. Although several studies have shown beneficial effects of TZD on experimental animal models of atherosclerosis, differences in cardiovascular risks among TZD were reported in clinical studies. Further studies are required to clarify the differences among the effects of TZD on diabetic macrovascular complications. Recently, a report showed that not the short-term use, but the use for more than 2 years of pioglitazone was weakly associated with an increased incidence of bladder cancer in a cohort study 162 . In contrast, statins, telmisartan and nifedipine, which possess the ability to activate PPARc, do not appear to mediate bodyweight gain, edema or incidence of cancers in clinical use. Thus, PPARc activation mediated by drugs other than TZD, such as statins, nifedipine and telmisartan, might be useful for the prevention of atherosclerosis without severe sideeffects. In any case, many in vitro, in vivo and clinical studies have proposed the validity of PPARc activation in the progression of atherosclerosis. Therefore, a therapeutic approach using PPARc activation for diabetic macrovascular complications might produce beneficial effects in patients with diabetes.
